Retatrutide, demystified
Tirzepatide was an iteration. Retatrutide is a category shift.
// tl;dr
Retatrutide hits three metabolic receptors instead of one or two. In the Phase 2 trial, the highest dose produced 24% mean weight loss at 48 weeks - past what Ozempic or Mounjaro deliver.
Tirzepatide established that dual receptor agonists outperform GLP-1 mono-agonists for weight loss. The Phase II data on Retatrutide - a triple agonist - suggests we have barely started to understand what is possible when peptides target multiple metabolic axes at once.
A brief history of the class#
GLP-1 receptor agonists (Liraglutide, Semaglutide) demonstrated that incretin-based therapies could produce sustained weight loss. Dual agonists like Tirzepatide added GIP receptor activation and roughly doubled the magnitude of effect. Retatrutide adds a third axis - glucagon receptor activation - and the Phase II results suggest another step change.
Eli Lilly's Phase II data, published in NEJM in 2023, showed 24% mean body weight reduction at 48 weeks at the highest dose.[1] Phase III trials are ongoing. The reference comparator is SURMOUNT-1, the Phase 3 trial for Tirzepatide.[2]
The three axes, mechanistically#
GLP-1#
Glucagon-like peptide-1 acts through several pathways. It enhances glucose-dependent insulin secretion, slows gastric emptying, suppresses inappropriate glucagon release, and acts centrally to reduce appetite. The cumulative effect: reduced intake plus improved glucose handling.
GIP#
Gastric inhibitory polypeptide was historically considered an obesity-promoting hormone in healthy individuals. Tirzepatide development surprised the field by showing that GIP agonism, when paired with GLP-1 agonism, augments weight loss rather than blunting it. The mechanism is still being worked out, but it likely involves effects on lipid handling and central appetite signaling.
Glucagon#
This is the addition that makes Retatrutide categorically different. Glucagon, the hormone that opposes insulin, also increases resting energy expenditure when activated peripherally. It mobilizes hepatic glycogen and drives lipolysis directly. In Retatrutide, the glucagon component is balanced against the GLP-1 component so that improvements in glucose handling are preserved - but the energy expenditure increase is captured.
What the data actually shows#
From the Phase II results (Lilly, NEJM 2023):
- 24.2% mean body weight reduction at 12 mg dose, 48 weeks
- Effects on triglycerides, blood pressure, and HbA1c at or exceeding Tirzepatide
- Side effect profile dominated by GI events (nausea, vomiting) - common to the class
- Discontinuation rates manageable with proper titration
Why this is not on shelves yet#
Retatrutide is in Phase III. FDA approval is anticipated in the 2026-2027 window, pending the Phase III readouts. Until then, the molecule is available only through research channels.
What that means practically: dosing protocols are still being established in clinical settings. Underground use is happening, but the safety and efficacy data outside of carefully controlled trials is essentially zero. Anyone using Retatrutide right now is, in effect, participating in an uncontrolled experiment with themselves.
How we think about it#
Retatrutide is the most consequential peptide we will have offered when it launches - both in terms of mechanism and demand. We are tracking the Phase III data closely. The brands rushing to market with it are not doing science. They are doing speculation, with biology. The market urgency they feel does not apply to us.
// the takeaway
Retatrutide is not another GLP-1. It is the first peptide that targets three metabolic receptor axes simultaneously. Phase II data shows roughly double the weight-loss magnitude of single-agonist approaches. It is not approved yet. We will release it when we can do so responsibly - not before.
// concerns researched
Does GLP-1-driven weight loss cost you bone density?#
Weight loss from any cause reduces the mechanical load on bone and tends to reduce BMD. The picture for GLP-1 receptor agonists specifically is mixed and depends on the population. A 2024 JAMA Network Open RCT in non-diabetic obesity found liraglutide alone reduced BMD at clinically relevant sites despite similar weight loss to exercise; combining liraglutide with exercise preserved bone. A 2025 meta-analysis in type-2 diabetes patients found no increase in fracture risk and even improvements in BMD at some sites. Recent critical reviews flag GLP-1 mono-agonists as showing neutral-to-negative bone effects, and note that dual- and triple-agonist molecules may have a different profile - though that profile has not yet been directly characterized for Retatrutide.
// we surface open questions, not recommendations. for research purposes only.
// selected research
click to expand
24.2% mean body weight reduction at 48 weeks on the 12 mg dose. The Phase 2 readout cited throughout this post.
open on pubmed· PMID 37366315SURMOUNT-1, the reference Phase 3 trial for the dual-agonist class. Useful as the comparator against which Retatrutide is judged.
open on pubmed· PMID 35658024
// for research purposes. nothing in this article is medical advice.